Month: May 2024

ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the first quarter ended March 31, 2024. Mark Duff, President and CEO of the Company, commented, “As previously disclosed, our financial performance in the first quarter of 2024 was impacted by a few temporary headwinds. However, we have seen steady improvement heading into the second quarter and anticipate a strong second half of 2024. The weakness we experienced was due in part to delayed project starts and waste shipments, as well as challenging weather conditions during the first quarter of 2024. However, we used this period for equipment replacement and repairs, program enhancements, and testing to support permit expansion and broader market penetration....

Company maintains solid cash position of $141.6 million SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024. The Company also announced today that it has decided to close and unblind both its Phase 2b clinical trial of zelnecirnon (RPT193) in atopic dermatitis (“AD”) and its Phase 2a trial of zelnecirnon in asthma. Both clinical trials were placed on clinical hold by the FDA in February 2024 based on a serious adverse event of liver failure requiring transplant in one patient in the AD trial....

— Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT– — On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 — — Dosed first patients in TANDEM, pivotal Phase 3 trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 — — Company to host R&D event on May 16, 2024, beginning at 9:00 a.m. ET in New York City – — Strong financial position; ending the quarter with $481.1 million in cash — NAARDEN, the Netherlands and MIAMI, May 09, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular...

– Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 – Received $50 million milestone following initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) – Clinical development milestones met and remain on track for the rest of the year for AAV-hAQP1 for RIX, bota-vec for XLRP, and AAV-GAD for Parkinson’s disease LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended...

Investor Call Today at 11am ET; Dial-in: 1-844-834-0644 WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN) (Acorn), a provider of remote monitoring and control solutions for backup power generators, gas pipelines, air compressors and other mission critical assets, announced results for its first quarter ended March 31, 2024 (Q1’24) and will hold an investor call today at 11am ET (see call details below). Summary Financial Results    Q1’24     Q1’23     Change      (dollars in thousands)Monitoring revenue   $ 1,102     $ 1,024         +7.6 %Hardware revenue     1,030       725         +42.1 %Total revenue*   $ 2,132     $ 1,749         +21.9 %Gross profit Margin     74.6 %     75.2 %        Net income (loss) attributable to Acorn stockholders   $ 65     $ (85 )       +$150                           Net...

Total First Quarter Revenue of $25.0 millionillumin Self-Service Revenue up 282% YoY (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 HighlightsFirst quarter 2024 revenue was $25.0 million, a decrease of 5.8% year-over-year, reflecting a decline in managed service and programmatic revenues – specifically in economically challenged markets within Latin America. illumin self-serve revenue was $8.4 million in the quarter, or 33.6% of total revenue, and was up 282% versus...

– Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 – – Conference Call Today at 8:30 a.m. ET – ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. Key HighlightsThe BHC-202 3-arm study comparing two dose levels of the valacyclovir/celecoxib combination vs placebo over 12 weeks to treat symptoms of LC is being conducted by the Bateman Horne Center...

Reiterating Revenue Growth throughout the Year MIGDAL HAEMEK, Israel, May 09, 2024 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the first quarter ended March 31, 2024. First Quarter of 2024 Results Overview Revenue for the first quarter of 2024 was $327 million as compared to $352 million for the fourth quarter of 2023. Revenue for the first quarter of 2023 was $356 million. Gross profit for the first quarter of 2024 was $73 million as compared to $84 million for the fourth quarter of 2023. Gross profit for the first quarter of 2023 was $96 million. Operating profit for the first quarter of 2024 was $34 million, as compared to $45 million in the fourth quarter of 2023. Operating profit for the first quarter of 2023 was $89 million and included $32 million restructuring income,...

– Full Year 2024 Sales Increase 8% to a Record $1.05 Billion ––38% Growth in E-Mobility Drives 17% Year-over-Year Increase in Full Year 2024 Automotive Sales – MANCHESTER, N.H., May 09, 2024 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its fourth quarter and full year ended March 29, 2024. “Continued strong momentum in e-Mobility drove record fiscal year 2024 sales to more than $1 billion and record non-GAAP earnings per share of $1.35. We also achieved a record level of design wins of more than $1 billion. I would like to thank the entire Allegro team for their contributions which enabled us to achieve these significant milestones,” said...